STOCK TITAN

Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.

Overview

Ginkgo Bioworks Holdings Inc (NYSE: DNA) stands as a pioneering platform in cell programming, expertly harnessing synthetic biology and biosecurity to engineer new organisms designed to solve complex challenges across diverse industries. With a robust in-house pipeline that spans the design, build, and test phases, Ginkgo leverages state-of-the-art biological engineering techniques to deliver end-to-end solutions for sectors as varied as pharmaceuticals, food and agriculture, industrial chemicals, and specialty chemicals.

Business Model and Core Segments

Ginkgo organizes its operations into two primary business segments: Cell Engineering and Biosecurity. The Cell Engineering segment provides comprehensive R&D services, offering clients custom development of engineered organisms for improved process efficiency and product innovation. Meanwhile, the Biosecurity segment addresses the growing need for biological threat mitigation, delivering services that include monitoring, detection, and rapid response to safeguard public health and industrial operations. This bifurcated approach enables Ginkgo to generate revenue through contract-based services, strategic partnerships, and licensing agreements, thereby establishing a versatile platform for a wide array of customers.

Industry Impact and Technological Innovation

At the core of Ginkgo’s operations is a commitment to transforming biology through technological innovation. The company integrates advanced automation, high-throughput screening, and data analytics to accelerate the engineering of biological systems. Their proprietary cell programming platform, augmented by AI-driven tools such as protein language models and model APIs, empowers researchers in drug discovery and bioprocess optimization. By streamlining complex workflows, Ginkgo not only reduces the cost and time required for R&D but also fosters a new era of scalable, digitalized biology research.

Comprehensive Services and Strategic Partnerships

Ginkgo Bioworks distinguishes itself by offering a full spectrum of services—from engineering novel enzymes and proteins to developing robust biological data platforms that underpin modern AI applications. The company has forged strategic partnerships with prominent industry players, including collaborations with technology giants and renowned pharmaceutical companies, which reinforce its reputation as an integrative innovator. Such alliances enable Ginkgo to expand its research capabilities and bring advanced bioengineering solutions to markets ranging from agricultural feed additives to sophisticated healthcare diagnostics.

Competitive Positioning and Market Differentiation

In a competitive biotechnology landscape, Ginkgo’s comprehensive suite of services and its ability to couple biological expertise with cutting-edge technology provide a significant edge. Their approach combines academic rigor, deep domain expertise, and practical application of synthetic biology, setting them apart from companies that focus on single facets of the biotechnological chain. Key differentiators include:

  • End-to-End Solutions: From organism design to scale-up manufacturing, providing seamless integration across multiple stages.
  • Advanced Automation: Utilization of high-throughput systems and custom automation services that significantly enhance research productivity.
  • AI Integration: Deployment of machine learning models and data-as-a-service offerings that optimize biological research and operational efficiency.
  • Robust Research and Development: Continuous investment in innovative R&D to both refine existing processes and develop transformative bioengineering technologies.

This integrated approach not only bolsters their technical prowess but also instills confidence in their ability to manage complex challenges in cell programming and biosecurity. Their interdisciplinary teams, which merge the insights of biology, chemistry, engineering, and computer science, ensure that they remain at the forefront of technological advancements and industry trends.

Conclusion

Ginkgo Bioworks exemplifies a modern biotechnology firm that leverages the power of synthetic biology and automation to unlock new frontiers in industrial and healthcare applications. Its dual-segment strategy, combining Cell Engineering and Biosecurity, coupled with significant advancements in AI and high-throughput data generation, positions the company as a formidable force in the biotech landscape. By offering comprehensive, scalable, and innovative bioengineering solutions, Ginkgo continues to enable transformative progress across a host of industries, solidifying its reputation as a trusted partner for organizations intent on redefining how biology is engineered to meet the world’s most challenging needs.

Rhea-AI Summary
Foremost Farms USA (NYSE: DNA) and Ginkgo Bioworks Partner to Upcycle Dairy Co-products into Value-Added Materials, Reducing Carbon Footprint and Lowering Manufacturing Costs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.44%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) added 21 new Cell Programs to the Foundry platform in Q3 2023 and entered into a strategic cloud and AI partnership with Google Cloud. They also signed a new multi-target RNA drug discovery collaboration with Pfizer, with potential payments of up to $331 million. Ginkgo ended Q3 2023 with over $1.0 billion in cash and cash equivalents, maintaining a multi-year runway as they continue to drive towards profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.44%
Tags
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on November 8, 2023, to review business performance for Q3 2023. The session will begin at 5:30 p.m. ET and will be available on Ginkgo's investor relations website. Questions can be submitted via Twitter or email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
Rhea-AI Summary
Ginkgo Bioworks partners with Penn State University to integrate biosurveillance capabilities into research of 58 wildlife species for SARS-CoV-2. The initiative aims to monitor potential spillover to humans and prevent the spread of new variants. The research will provide data for informed decision-making by public health officials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
partnership
-
Rhea-AI Summary
Ginkgo Bioworks and the Government of Serbia have entered into a Memorandum of Understanding to collaborate on Serbia's bioeconomy vision. They will establish a Startup Accelerator leveraging Ginkgo's platform to support Serbian companies building with biology. Serbia's BIO4 campus initiative aims to make Serbia a bioeconomy hub in Europe and has already signed MoUs with various companies. Ginkgo will offer flexible services to companies at BIO4 and explore partnerships to develop biomonitoring capabilities in Serbia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
Rhea-AI Summary
Persephone Biosciences and Ginkgo Bioworks complete their collaboration on a Bacteroides engineering toolkit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks and Zenfold Sustainable Technologies collaborate to develop sustainable manufacturing technology for veterinary products
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
none
-
Rhea-AI Summary
QL AG announces collaboration with Ginkgo Bioworks to develop dairy proteins
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
partnership
-
Rhea-AI Summary
Ginkgo Bioworks partners with Northeastern University to develop technologies for early warning and epidemic forecasting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
AI
Rhea-AI Summary
German startup Nosh.bio partners with Ginkgo Bioworks to develop mycoprotein for animal-free food products. Nosh.bio aims to create a single-ingredient alternative to red meat that is healthier and tastes like real meat. Ginkgo's screening technology will help discover a superior strain of fungi for this purpose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none

FAQ

What is the current stock price of Ginkgo Bioworks Holdings (DNA)?

The current stock price of Ginkgo Bioworks Holdings (DNA) is $5.66 as of April 1, 2025.

What is the market cap of Ginkgo Bioworks Holdings (DNA)?

The market cap of Ginkgo Bioworks Holdings (DNA) is approximately 324.4M.

What is the core business of Ginkgo Bioworks?

Ginkgo Bioworks operates as a platform for cell programming, using synthetic biology to engineer organisms that address challenges across diverse industries.

Which key segments does Ginkgo organize its operations into?

The company is structured around two primary segments: Cell Engineering, which offers custom biological R&D services, and Biosecurity, which focuses on monitoring and mitigating biological threats.

How does Ginkgo Bioworks generate revenue?

Revenue is derived from a combination of contract-based R&D services, strategic partnerships, and licensing arrangements, all focused on enhancing biological processes and biosecurity solutions.

What industries benefit from Ginkgo's services?

Their end-to-end bioengineering solutions serve a broad array of industries including pharmaceuticals, food and agriculture, industrial chemicals, and specialty chemicals.

How does Ginkgo incorporate advanced technology into its offerings?

The company integrates automation, high-throughput screening, and AI-driven tools such as protein language models and data platforms to streamline biological research and accelerate innovation.

How is Ginkgo differentiated from its competitors?

Ginkgo stands out by combining comprehensive R&D services with a strong emphasis on automation and AI integration, supported by strategic partnerships and interdisciplinary expertise.

Can you elaborate on Ginkgo's approach to synthetic biology?

Ginkgo utilizes an in-house pipeline for designing, building, and testing new organisms, enabling them to tailor cell-based solutions that meet the specific needs of various markets.

Who are the typical clients of Ginkgo Bioworks?

Their clients range from government agencies requiring biosecurity solutions to biotech and pharmaceutical companies, as well as organizations in agriculture and industrial sectors seeking innovative biological engineering services.
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

324.41M
54.25M
6.6%
79.85%
15.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON